The residual risk of transfusion-transmitted cytomegalovirus infection associated with leucodepleted blood components

Vox Sanguinis

Volumn 109, Issue 1, 2015, Pages 11-17

  Seed, C R ^a   Wong, J ^a   Polizzotto, M N ^b   Faddy, H ^a   Keller, A J ^a   Pink, J ^a  

^a AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Blood safety; Leucodepletion; Residual risk estimation; Transfusion transmissible infection

Indexed keywords

VIRUS DNA;

ARTICLE; AUSTRALIA; BLOOD COMPONENT; BLOOD COMPONENT LEUCODEPLETION; BLOOD DONOR; BLOOD TRANSFUSION; CYTOMEGALOVIRUS INFECTION; ERYTHROCYTE; HEMATOLOGICAL PROCEDURE; HUMAN; INFECTION RISK; LEUKOCYTE; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; PROCESS CONTROL; RESIDUAL RISK; THROMBOCYTE; TRANSFUSION TRANSMITTED CYTOMEGALOVIRUS INFECTION; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS TRANSMISSION; ANIMAL; BLOOD COMPONENT THERAPY; CYTOLOGY; CYTOMEGALOVIRUS; IMMUNOLOGY; MOUSE; RISK; TRANSMISSION;

ANIMALS; BLOOD COMPONENT TRANSFUSION; BLOOD DONORS; BLOOD PLATELETS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ERYTHROCYTES; HUMANS; LEUKOCYTES; MICE; RISK;

EID: 84931564872     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12250     Document Type: Article

References (34)

1. Pass RF: Cytomegalovirus; Fields Virology. Philadelphia, Lippincott- Williams and Wilkins, 2001:2675-2705
2. Preiksaitis JK: Indications for the use of cytomegalovirus-seronegative blood products. Transfus Med Rev 1991; 5:1-17
3. Drew WL, Roback JD: Prevention of transfusion-transmitted cytomegalovirus: reactivation of the debate? Transfusion 2007; 47:1955-1958
4. Sinclair J: Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol 2008; 41:180-185
5. Yeager AS, Grumet FC, Hafleigh EB, et al.: Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981; 98:281-287
6. Roback JD: CMV and blood transfusions. Rev Med Virol 2002; 12:211-219
7. Adler SP: Transfusion-associated cytomegalovirus infections. Rev Infect Dis 1983; 5:977-993
8. Huang ES, Huong SM, Tegtmeier GE, et al.: Cytomegalovirus: genetic variation of viral genomes. Ann N Y Acad Sci 1980; 354:332-346
9. Drew WL, Tegtmeier G, Alter HJ, et al.: Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion 2003; 43:309-313
10. Ziemann M, Krueger S, Maier AB, et al.: High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007; 47:1972-1983
11. Ziemann M, Unmack A, Steppat D, et al.: The natural course of primary cytomegalovirus infection in blood donors. Vox Sang 2010; 99:24-33
12. Ziemann M, Heuft HG, Frank K, et al.: Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections. Transfusion 2013; 53:1088-1094
13. Ziemann M, Juhl D, Gorg S, et al.: The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients. Transfusion 2013; 53:2183-2189
14. James DJ, Sikotra S, Sivakumaran M, et al.: The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets. Transfus Med 1997; 7:123-126
15. Furui Y, Satake M, Hoshi Y, et al.: Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors. Transfusion 2013; 53:2190-2197
16. Vamvakas EC: Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 2005; 19:181-199
17. Blajchman MA, Goldman M, Freedman JJ, et al.: Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev 2001; 15:1-20
18. Roback JD, Josephson CD: New insights for preventing transfusion-transmitted cytomegalovirus and other white blood cell-associated viral infections. Transfusion 2013; 53:2112-2116
19. Ratko TA, Cummings JP, Oberman HA, et al.: Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion 2001; 41:1310-1319
20. Lieberman L, Devine DV, Reesink HW, et al.: Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: standards of care. Vox Sang 2014; 107:276-311
21. Wu Y, Zou S, Cable R, et al.: Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2010; 50:776-786
22. Seed CR, Piscitelli LM, Maine GT, et al.: Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion 2009; 49:134-145
23. Roback JD, Su L, Zimring JC, et al.: Transfusion-transmitted cytomegalovirus: lessons from the murine model. Transfus Med Rev 2007; 21:26-36
24. Zanghellini F, Boppana SB, Emery VC, et al.: Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999; 180:702-707
25. Boom R, Sol CJ, Schuurman T, et al.: Human cytomegalovirus DNA in plasma and serum specimens of renal transplant recipients is highly fragmented. J Clin Microbiol 2002; 40:4105-4113
26. Mood AM, Graybill FA, Boes DC: Introduction to the Theory of Statistics. McGraw Hill: Noida, India, 2001.
27. Calman KC: Cancer: science and society and the communication of risk. BMJ 1996; 313:799-802
28. Bowden RA, Slichter SJ, Sayers M, et al.: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86:3598-3603
29. Cytomegalovirus tested blood components - a position statement. London, UK Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO), 2012- available at https://www.gov.uk/government/publications/sabto-report-of-the-cytomegalovirus-steering-group
30. Kekre N, Tokessy M, Mallick R, et al.: Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction? Biol Blood Marrow Transplant 2013; 19:1719-1724
31. Josephson CD, Castillejo MI, Caliendo AM, et al.: Prevention of transfusion-transmitted cytomegalovirus in low-birth weight infants (
32. Josephson CD, Caliendo AM, Easley KA, et al.: Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a Prospective Cohort Study. JAMA Pediatr 2014; 168:1054-1062
33. National Blood Authority: National Blood Supply Contingency Plan (Annex C- Section 9). Canberra, 2013. http://www.blood.gov.au/system/files/documents/nba-nbscp-annex-c-platelets_0.pdf (Last accessed 16 September 2014 2014)
34. Ziemann M, Hennig H: Prevention of transfusion-transmitted cytomegalovirus infections: which is the optimal strategy? Transfus Med Hemother 2014; 41:40-44